Researchers have identified genetic variants in the parasite Schistosoma mansoni that may reduce its sensitivity to praziquantel, the sole drug used to treat schistosomiasis. This discovery, based on whole-genome sequence data from 570 parasites across Africa and the Caribbean, signals potential resistance to praziquantel, threatening global health programs' reliance on this medication.
Health organizations should implement genomic surveillance to monitor and address emerging drug resistance in S. mansoni populations.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
4
Ali NematiWritten by Ali
